Rivastigmine, a cholinesterase inhibitor, may modestly improve dementia symptoms or slow decline, but it can cause digestive problems, weight loss, and dehydration. The patch may suit people with mild-to-severe Alzheimer's dementia or mild-to-moderate Parkinson's disease dementia, but not mild cognitive impairment alone. Rivastigmine is not a cure. Some people improve or decline more slowly, while others gain no noticeable benefit, and Alzheimer's disease continues to worsen over time.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What benefit is realistic?
- Who may qualify?
- What are the main risks?
- How is the patch started and adjusted?
- Preventing patch errors
What benefit is realistic?
Rivastigmine supports the brain chemicals involved in memory and thinking. Its goal is symptomatic benefit: preserving cognition, daily function, or overall stability for a time rather than stopping the underlying disease. In a 24-week Alzheimer's trial involving 1,195 people, the 9.5-mg/day patch produced a 1.8-point cognitive advantage over placebo. It also produced a statistically significant difference in overall clinical status, according to the FDA-approved prescribing information.
A Cochrane review of mild-to-moderate Alzheimer's disease found benefits in cognition, daily activities, and clinician-rated overall change at about 26 weeks. However, the average cognitive effect was modest, so families should not expect a dramatic return to earlier abilities. For severe Alzheimer's disease, a 24-week trial found that the 13.3-mg/day patch slowed declines in cognition and daily function more than the 4.6-mg/day patch. That comparison does not mean every person will tolerate or benefit from the higher dose.
Who may qualify?
In the United States, DailyMed lists the rivastigmine patch for mild, moderate, or severe Alzheimer's dementia and mild-to-moderate Parkinson's disease dementia. It is not labeled for mild cognitive impairment without a qualifying dementia diagnosis.
Several factors require extra caution: Rivastigmine should not be used after an allergy to the drug or after allergic contact dermatitis caused by its patch. These are different from mild, temporary skin irritation and need review before further exposure.
- Body weight below 50 kilograms, or about 110 pounds
- Liver impairment
- A history or risk of ulcers or bleeding
- Asthma or chronic obstructive pulmonary disease
- Seizure risk
What are the main risks?
Nausea, vomiting, diarrhea, reduced appetite, weight loss, and dehydration are central concerns. These effects are dose-related, making careful monitoring especially important after treatment begins or the dose rises. In one trial, 8% of people using the 9.5-mg/day patch lost at least 7% of their starting weight, compared with 6% receiving placebo.
Caregivers can help by watching appetite, fluid intake, bowel symptoms, vomiting, and weight. Repeated vomiting, diarrhea, poor intake, or noticeable weight loss warrants prompt contact with the prescriber. A higher dose offers little practical value if adverse effects make it unsafe or unsustainable.
How is the patch started and adjusted?
Treatment generally begins with a 4.6-mg/24-hour patch. If it is tolerated, the prescriber waits at least four weeks before each increase; 9.5 mg/24 hours is considered the minimum effective dose. Some people with severe Alzheimer's disease may qualify for the 13.3-mg/24-hour patch.
Dose decisions should balance possible functional benefit against appetite, weight, hydration, and other medical risks. An interruption changes the dosing plan. If treatment stops for more than three days, it must restart at 4.6 mg/24 hours rather than immediately resuming the previous dose.
Preventing patch errors
Only one rivastigmine patch should be worn at a time, and it should be replaced every 24 hours. The caregiver should remove the old patch before applying the new one and check the skin carefully if the previous patch is difficult to see.
Wearing multiple patches or leaving an old patch in place has caused serious overdoses, hospitalization, and, rarely, death, according to the FDA label's patch-safety warning. A simple daily patch log can record when the old patch was removed and where the new one was applied.
